Literature DB >> 10543630

MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing.

I Catalaa1, J C Fulton, X Zhang, J K Udupa, D Kolson, M Grossman, L Wei, J C McGowan, M Polansky, R I Grossman.   

Abstract

BACKGROUND AND
PURPOSE: Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous system and manifests both physical and neurocognitive disabilities. Although predominantly a disease of the white matter, MS is also characterized by lesions in the gray matter. Previous pathologic studies have found that cortical and deep gray matter lesions comprised 5% and 4%, respectively, of total lesions. Using software for lesion detection and quantitation, our study was designed to determine MS involvement in the cortical and deep gray matter and to correlate gray matter lesion load with neurocognitive function and the Kurtzke Expanded Disability Status Scale.
METHODS: Using a semiautomated segmentation algorithm that detected and delineated all possible brain MS lesions on MR images, we investigated gray matter lesion volume in 18 patients with untreated relapsing-remitting MS. Cortical and deep gray matter lesions then were correlated with the neurocognitive and physical disability measurements.
RESULTS: We found that cortical gray matter lesions comprised approximately 5.7% of the total lesion volume, whereas deep gray matter lesions comprised another 4.6% in this patient cohort. No strong correlations were found between gray matter lesions and disability status or neurocognitive function.
CONCLUSION: These results are similar to those found in previous pathologic studies. The cortical lesion load in cases of relapsing-remitting MS, as measured by MR imaging, represents less than 6% of the total lesion volume and does not correlate with disability measures or neurocognitive tests.

Entities:  

Mesh:

Year:  1999        PMID: 10543630

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  12 in total

Review 1.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

Review 2.  An artificial immune-activated neural network applied to brain 3D MRI segmentation.

Authors:  Akmal Younis; Mohamed Ibrahim; Mansur Kabuka; Nigel John
Journal:  J Digit Imaging       Date:  2007-12-11       Impact factor: 4.056

Review 3.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 4.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

5.  Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis.

Authors:  Y Ge; R I Grossman; J K Udupa; J S Babb; D L Kolson; J C McGowan
Journal:  AJNR Am J Neuroradiol       Date:  2001-03       Impact factor: 3.825

Review 6.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

7.  Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla.

Authors:  A Kangarlu; E C Bourekas; A Ray-Chaudhury; K W Rammohan
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

Review 8.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

9.  Estrogen treatment in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  J Neurol Sci       Date:  2009-06-18       Impact factor: 3.181

10.  Cognitive presentation of multiple sclerosis: evidence for a cortical variant.

Authors:  M Zarei; S Chandran; A Compston; J Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.